The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) with the International Antiviral Society developed a living document with ever evolving guidelines to treat HCV.
The guidelines have a complex algorithm for practitioners around the country to follow and see what's the right treatment, for the right patients, for the right about of time. The document is easy to comprehend, which benefit patients considering HCV therapy. When new HCV drugs are approved, and new real world data is established, the guidelines are updated.
What’s New and Updates/Changes
Wednesday, July 6, 2016
Download Updates, here..........
This version of the Guidance has been updated to reflect several important developments, including the recent approval of sofosbuvir/velpatasvir, together with new information regarding the use of testing for HCV resistance associated variants....
Updated recommendations reflecting this approval are provided in these sections:
Initial Treatment of HCV Infection
Retreatment of Persons in Whom Prior Therapy has Failed
Unique Patient Populations: Patients with Decompensated Cirrhosis
Other updates reflecting recent data are provided in:
Unique Patient Populations: Patients who Develop Recurrent HCV Infection Post-Liver Transplantation
Unique Patient Populations: Patients with HIV/HCV Coinfection
Unique Patient Populations: Patients with Renal Impairment
HCV Testing and Linkage to Care
Updated recommendations regarding the monitoring of cirrhotic patients are also provided in:
Monitoring Patients Who Are Starting Hepatitis C Treatment, Are On Treatment, or Have Completed Therapy
Drug-drug interaction updates are also provided, particularly as they relate to antiretroviral agents and calcineurin inhibitors in:
Unique Patient Populations: Patients with HIV/HCV Coinfection
Unique Patient Populations: Patients who Develop Recurrent HCV Infection Post-Liver Transplantation
No comments:
Post a Comment